Form 4: Mineralys CFO Adam Levy Boosts Stake with New Equity Awards

Mineralys Therapeutics CFO Adam Levy received significant equity awards, including 39,900 Restricted Stock Units and 53,300 stock options, as part of his compensation.

Summary

• Adam Scott Levy, Chief Financial Officer and Secretary of Mineralys Therapeutics, Inc. (MLYS), acquired new equity awards on February 19, 2026.
• The awards include 39,900 shares of Common Stock in the form of Restricted Stock Units (RSUs) granted at a price of $0.
• Also acquired were 53,300 stock options with an exercise price of $28.06 per share.
• The Restricted Stock Units (RSUs) are scheduled to vest in annual installments over a four-year period, with 1/4th of the total shares vesting on each one-year anniversary of the grant date.
• The stock options are scheduled to vest in monthly installments over a four-year period, with 1/48th of the total shares vesting each month following the grant date.
• Following these reported transactions, Levy beneficially owns 48,538 shares of Common Stock and 53,300 stock options.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, indicating management's continued commitment and alignment with the company's long-term success through equity ownership, which is generally favorable for investor confidence.

Positives

• Increased alignment of management's interests with shareholders through significant equity awards.
• The awards incentivize long-term performance and retention of a key executive, fostering stability in leadership.

Negatives

• No immediate cash inflow for the company from these grants, as RSUs are granted at $0 and options require future exercise.
• Potential future dilution for existing shareholders if the stock options are exercised and RSUs vest, increasing the total number of outstanding shares.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity compensation, such as RSUs and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate key executives. These awards align executive incentives with long-term shareholder value creation, a common strategy for growth-oriented companies like Mineralys Therapeutics.

Comparison to Industry Standards

• StockSavvy.ai observes that the vesting schedules (four years for both RSUs and stock options) are consistent with typical industry standards for executive equity compensation in the biotech sector, aiming to ensure long-term commitment and performance.

Stakeholder Impact

• Shareholders: Potential long-term benefit from aligned management incentives; potential future dilution from vesting awards.
• Employees: May signal stability and growth opportunities within the company, potentially boosting morale and retention.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a key executive, which is a standard practice to align management incentives with shareholder value. It does not present new information that would fundamentally alter the investment thesis for Mineralys Therapeutics, hence a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Mineralys Therapeutics, MLYS, Adam Levy, CFO, Restricted Stock Units, RSUs, Stock Options, Equity Awards, Insider Transaction, Executive Compensation